Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-003-3 | CAS number: 56519-71-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Short description of key information on bioaccumulation potential result:
1,3 propanediol dicaprylate is predicted to be not bio-accumulating. It is predicted to be absorbed after ingestion, dermal application and inhalation. Metabolism is initiated by enzymatic ester hydrolysis. The acid part is treated as a fatty acid and will be degraded to CO2 via the Krebs cycle. For propanediol, renal elimination of the mostly unchanged substance is expected. Slow oxidation of 1,3-propanediol by liver homogenates in vitro was reported and considered to be a minor pathway in vivo.
Key value for chemical safety assessment
Additional information
The toxicokinetic statement is based on the general knowledge of metabolism published in textbooks and in research publications. It is combined with information on target organ toxicity from animal studies of metabolites or related chemicals.
Assessment:
The only functional group contained in the main product of 1,3-propanediol dicaprylate is the ester bond. Ester bonds are stable to acidic hydrolysis and so after ingestion, 1,3-propanediol dicaprylate is expected to enter the intestine unchanged. It is likely that lipases produced by the bile will initiate ester hydrolysis in the small intestine (Mattson, 1972). Any intact 1,3-propanediol dicaprylate ester that is absorbed will be rapidly cleaved by esterases in the blood (Testa, 2003). Enzymatic ester hydrolysis is also expected after dermal application or inhalation (Oesch, 2007; Zhang, 2006), especially since it is sufficiently small for uptake. Indeed, modeling skin permeability using the model of Fitzpatrick (Fitzpatrick, 2004) shows moderate permeability. Due to the low vapour pressure of 7.9 x 10-4 Pa at room temperature, exposure via inhalation is of low relevance. It may be relevant if the substance is handled at high temperature.
Ester hydrolysis yields the octanoic acid which is a slightly shorter version of a normal fatty acid. It will be coupled with coenzyme A and degraded via ß-oxidation in the microsomes and the Krebs cycle. The diol is probably sufficiently small and soluble to become eliminated via the kidney without further metabolic transformation. However, alcohols may also undergo oxidation to the carbonic acid via the aldehyde. It was reported that 1,3-propanediol can be metabolized to malondialdehyde by liver homogenate at a rate of 5.6 nmol/h/100 mg tissue protein in vitro (Summerfield, 1984). Limited information on the design (eg optimization of assay conditions) is given. Considering the high concentration of 1,3-propanediol in this in-vitro assay, the slow turnover rate and the high water solubility, malondialdehyde formation is not expected to be a major metabolic pathway in vivo. The experimental data on 1,3-propanediol consistently shows absence of significant systemic toxicity (DuPont, 1,3-propanediol Health and Environmental Data Summary). This is supportive of easy and rapid elimination.
Repeated-dose toxicity information:
Subchronic oral toxicity study with structural analogue Decanoic acid, mixed diesters with octanoic acid and propylene glycol (Pittermann, 1993) :
The subchronic toxicity study was performed according to guideline OECD 408 under GLP. Decanoic acid, mixed diesters with octanoic acid and propylene glycol was administered by gavage to each ten male and female rats at doses of 0, 100, 300 or 1000 mg/kg bw per day for 90 days. The NOAEL was 1000 mg/kg bw.
Prenatal development toxicity with structural analogue Decanoic acid, mixed diesters with octanoic acid and propylene glycol (Pittermann, 1994) :
The embryotoxicity study including teratogenicity was performed according to guideline OECD 414 under GLP. Female rats wre treated by oral gavage with 100, 300 or 1000 mg/kg bw from day 6 to day 15 of gestation. The NOAEL for both maternal toxicity and developmental toxicity was 1000 mg/kg bw, corresponding to the highest dose tested.
Subchronic oral toxicity study with 1,3-Propanediol (Gingell, 2000):
The subchronic toxicity study was performed according to GLP and the EPA Toxic Substances Control Act Health Effects Testing Guidelines. 1,3-Propanediol was given by gavage to groups of each ten male and female rats at doses of 0, 100, 300 or 1000 mg/kg bw per day. The no-observed-effect-level was 1000 mg/kg bw.
Teratogenicity study with 1,3-Propanediol (Leuschner, 1992):
The teratogenicity study was performed according to OECD guideline 414 and GLP. In this study, female rats were treated by oral gavage with 250 or 1000 mg/kg bw from day 6 to day 15 of gestation. All animals survived the treatment, and 250 mg/kg bw was identified as the no-observed effect level. At 1000 mg/kg bw, a slight decrease in body weight gain was noted. Teratogenic findings were not observed.
This study shows that pregnant female rats tolerate a 9-day treatment of 250 mg/kg bw without indication of toxicity.
Two-weeks inhalation study with 1,3-Propanediol (Scott, 1998):
The inhalation study was performed according and GLP. In this study, ten male rats were exposed nose-only to vapor only or a vapor /aerosol mixture in air at concentrations of 41, 650 and 1800 mg/m3 as analytically verified. During the two weeks, nine treatments of each 6 hours were performed and the following parameters were recorded: urinalysis at the last day of exposure, all standard haematology parameters, clinical signs of toxicity, body weight determination, organ weights of liver, kidneys, lung, testes and brain, as well as histopathology of nose, pharynx/larynx, lungs, livers, testes and gross lesions. All animals survived the treatment, and 1800 mg/m3 air was identified as the no-observed effect level.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.